PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

P-CABs Outperform PPIs in Clarithromycin-Resistant H. pylori

vonoprazantegoprazankeverprazanpotassium-competitive acid blockersproton pump inhibitorsHelicobacter pyloriclarithromycin resistanceeradication therapyamoxicillinbismuth quadruple therapymeta-analysisantimicrobial stewardship Infectious Disease / Antimicrobials

Background Information

P-CABs are more effective than PPIs against resistant Helicobacter pylori.

Clarithromycin-resistant Helicobacter pylori infections are challenging to treat, and finding effective eradication regimens is crucial. P-CAB-based regimens significantly improved eradication rates in resistant infections (74.7% vs 52.7% for PPIs, RR 1.42; 95% CI 1.14-1.76). Further studies are needed to optimize antibiotic combinations and treatment durations. Current evidence supports P-CABs' superiority in resistant infections. P-CABs outperform PPIs in eradication regimens for clarithromycin-resistant Helicobacter pylori.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Andreev DN, Khurmatullina AR, Bordin DS, Zaborovsky AV, Sokolov PS, Kucheryavyy YA, Beliy PA, Maev IV

Citation: Andreev DN, Khurmatullina AR, Bordin DS, et al. Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in Eradication Regimens for Clarithromycin-Resistant Helicobacter pylori: A Systematic Review and Meta-Analysis. Pathogens (Basel, Switzerland). 2026;15(9). doi:10.3390/pathogens15090986

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.